Serum carotenoids and fatty acids concentrations, macular pigment and visual function in people with long-term computer display light exposure lutein, zeaxanthin, omega-3 polyunsaturated fatty, macular pigment, visual function, light exposure
Conditions
Interventions
100 participants receive 6 mg daily lutein ester and 3 mg daily beta-carotene for 24 weeks,100 participants receive 12 mg daily lutein for 24 weeks,100 participants receive 24 mg daily lutein ester an
Active Comparator Dietary Supplement,Active Comparator Dietary Supplement,Active Comparator Dietary Supplement,Active Comparator Dietary Supplement,Active Comparator Dietary Supplement,Placebo Compara
Intervention name: Lutein ester and beta-carotene group,Lutein group,Lutein ester and zeaxanthin group,Lutein and zeaxanthin group,Lutein, zeaxanthin, DHA and EPA group,Intervention name: Placebo
Sponsors
BYHEALTH Institute of Nutrition & Health
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) Individuals aged between18 and 45 years who has a screen time of more than 8 h/day within two years 2) were able and willing to consent to both the qualification and the randomization/follow-up phases of the study 3) were likely, willing and able to undergo examinations for at least three times 4) agreed to stop current use of supplements containing lutein, zeaxanthin, omega-3 LCPUFAs (specifically DHA and EPA), beta-carotene, other than those supplied by our study
Exclusion criteria
Exclusion criteria: 1) A chronic requirement for any systemic or ocular medication administered for other diseases and known to be toxic to the retina or optic nerve 2) Previous daily supplementation with lutein and/or omega-3 LCPUFAs within six months 3) History of ocular trauma or eye surgery 4) A chronic requirement for any systemic or ocular medication administered for other diseases and known to be toxic to the retina or optic nerve 5) Any condition that would make adherence or follow-up difficult or unlikely
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum carotenoids and fatty acids concentrations At baseline, 12 weeks, and 24 weeks during the intervention High performance liquid chromatography,Macular pigment optical density At baseline, 12 weeks, and 24 weeks during the intervention MPS II,Uncorrected visual acuity At baseline, 12 weeks, and 24 weeks during the intervention ETDRS chart,Corrected visual acuity At baseline, 12 weeks, and 24 weeks during the intervention ETDRS chart,Contrast sensitivity At baseline, 12 weeks, and 24 weeks during the intervention CSV-1000,Glare sensitivity At baseline, 12 weeks, and 24 weeks during the intervention CSV-1000 | — |
Secondary
| Measure | Time frame |
|---|---|
| Dietary carotenoid and omega-3 intake At baseline, 12 weeks, and 24 weeks during the intervention Food frequency questionnaire,Dry eye assessment At baseline, 12 weeks, and 24 weeks during the intervention The Ocular Surface Disease Index and OCULUS Keratograph,Macular thickness At baseline, 12 weeks, and 24 weeks during the intervention Optical coherence tomography,Visual quality At baseline, 12 weeks, and 24 weeks during the intervention Optical quality analysis system and OPD Scan ,Key gene related to the effect of the intervention At baseline Genome-wide association studies | — |
Countries
China
Contacts
Public ContactLe Ma
Xi'an Jiaotong University Health Science Center
Outcome results
None listed